Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 50 million

Carnegie acted as sole manager and sole book-runner in the directed new share issue of 2.5 million new shares at a subscription price of SEK 20 per share. Oasmia develops novel formulations of already established cytostatics for both human and veterinary use, which in comparison to current alternatives show improved performance, a reduced side-effect profile and an expanded therapeutic area.July 2014.